drugset / Trial / NCT01681121

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

NCT01681121

Phase 2 Completed 93 enrolled Jazz Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a study to evaluate the safety and effectiveness of ADX-N05 compared to placebo in the treatment of excessive daytime sleepiness in adults with narcolepsy.

Timeline

Start
2012-09
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Solriamfetol Small molecule 300 mg Oral

Indications